상세 보기
Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
- Abramson, Jeremy;
- Ku, Matthew;
- Fox, Christopher;
- Huang, Huiqiang;
- Zhang, Huilai;
- ... Kim, Won-Seog;
- 외 14명
Citations
WEB OF SCIENCE
0Citations
SCOPUS
0- 제목
- Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
- 저자
- Abramson, Jeremy; Ku, Matthew; Fox, Christopher; Huang, Huiqiang; Zhang, Huilai; Townsend, William; Yoon, Dok Hyun; Kim, Won-Seog; Abdulhaq, Haifaa; Herbaux, Charles; Zaucha, Jan; Chang, Hung; Mulvihill, Estefania; Kesavan, Murali; Kallemeijn, Martine Joanna; Ta, Richard; Choeurng, Voleak; Bottos, Alessia; Lundberg, Linda; Gregory, Gareth P.
- 발행일
- 2025-11-03
- 유형
- Meeting Abstract
- 저널명
- Blood
- 권
- 146